Miranda Bishara, MD
Ophthalmology · Prairie Village, KSNPI 1437191988
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,514 of the $44,948 with a category attached, or 76.8%. Ocular Therapeutix, Inc. accounts for 87.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $25,072 and has fallen 63.1% since, to $9,239 in 2025. Among ophthalmology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $293.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$39K
- Alcon$3K
- Sun Pharmaceutical Industries Inc.$463
- Kala Pharmaceuticals, Inc.$261
- Glaukos Corporation$258
- AbbVie$256
- plus $1K from 18 others
What the payments were for
- Consulting fees$500%
- Speaking & faculty fees$34,51477%
- Travel & lodging$4,96911%
- Food & beverage$5,41512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 33 | $39,463 |
| Alcon | 47 | $2,823 |
| Sun Pharmaceutical Industries Inc. | 14 | $463 |
| Kala Pharmaceuticals, Inc. | 3 | $261 |
| Glaukos Corporation | 4 | $258 |
| AbbVie(2 entities) | 8 | $256 |
| Bausch & Lomb Americas Inc. | 6 | $212 |
| Amgen(2 entities) | 4 | $178 |
| Rxsight Inc | 4 | $173 |
| Abbott | 3 | $160 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $125 |
| Oyster Point Pharma, Inc. | 4 | $81 |
| Dompe US, Inc. | 3 | $73 |
| Harrow Eye, LLC | 3 | $69 |
| Novartis | 4 | $66 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $56 |
| Carl Zeiss Meditec USA, Inc. | 1 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| The Cameron-ehlen Group, Inc. | 1 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
| Sight Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$39,324
- Clareon$521
- Ophthalmic Surgical Adjuncts$375
- CEQUA$245
- ARGOS$150
- AcrySof IQ PanOptix UV IOL$149
- AcrySof IQ VIVITY$149
- Clareon PanOptix Pro$143
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$132
- Wavelight$128
- INVELTYS$126
- OZURDEX$125
- Centurion$125
- EYSUVIS$118
- TEPEZZA$116
- MIEBO$115
- XIIDRA$115
- CardioMEMS HF System$114
How this compares
$44,948 in reported general payments places this provider in the 95th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 59 | $71,995 |
| Prednisolone Acetate | 902 | $31,605 |
| XiidraLifitegrast | 20 | $20,338 |
| LumiganBimatoprost | 26 | $10,335 |
| IlevroNepafenac | 26 | $9,737 |
| Cyclosporine | 17 | $9,336 |
| Ketorolac Tromethamine | 386 | $9,311 |
| ValacyclovirValacyclovir Hcl | 132 | $6,961 |
| Travoprost | 32 | $4,666 |
| ProlensaBromfenac Sodium | 13 | $4,523 |
| Tobramycin | 436 | $2,375 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,238 |
| Bromfenac Sodium | 14 | $1,725 |
| Gatifloxacin | 20 | $1,552 |
| Famciclovir | 20 | $1,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $256 | $82,33085 claims |
| Bausch & Lomb Americas Inc.Xiidra | $212 | $20,33820 claims |
| NovartisIlevro | $66 | $9,73726 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $56 | $4,52313 claims |
| AlconSimbrinza | $2,823 | $2,23811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Prairie Village
- Jason SokolPrairie Village$12K
- Anjulie QuickPrairie Village$3K
- Daniel DurrieOverland Park$974K
- John DoaneLeawood$496K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
- Jeff WongskhaluangOlathe$42K
- Michael EllisLenexa$38K
- Matthew SniegowskiLeawood$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.